R&D
Osteoporosis
Osteoporosis is a systemic skeletal disease characterized by a reduction of bone density and altred bone quality, with increased fracture risk.
Osteoporosis is a systemic skeletal disease characterized by a reduction of bone density and altred bone quality, with increased fracture risk.
A systemic skeletal disease characterized by:
- Reduction of bone density.
- Altered bone quality.
- Increased fracture risk .
The Number:
In developed countries, the lifetime risk for osteoporotic fractures at the wrist, hip or spine is 30% to 40%, very close to that for coronary heart disease.
An age-related disease
Osteoporosis is an age related disease and becomes more common in advanced age.
Meaning of fractures
Elderly suffering with femoral fractures die within a year (15-25%) or become dependent (50%). A single vertebral fracture doubles the risk of subsequent femoral fracture within a year. Multiple vertebral fractures impair patients’ quality of life and increase mortality.
Socioeconomic burden:
- Inhospital stay
- Rehabiltation costs
- Loss of indipendence
- Caregiver burden
- Increased mortality
The innovative solution
Novaicos aims to reduce the fracture incidence with an innovative pharmacological approach, is developing a new biological drug, biocompatible and modulable, reversible and efficacious.
ICOS-Fc work
ICOS-Fc inhibits bone resorpition and allows bone formation.
ICOS-Fc inhibit osteoclast formation and activity in vitro
ICOS-Fc directly inhibits the bone resorbing cells (osteoclasts) without toxic effect.
ICOS-Fc activity in models of bone erosion.
ICOS-Fc is able to restore bone structure in vivo in different mice models
of osteoporosis.
On Target
selective inhibits resorbing osteoclats
On Time
quick wash out (20 days) allows bone remodelling
